Active Biotech to Present at the Jefferies 2013 Global Healthcare Conference

        Print
| Source: Active Biotech AB
Lund, Sweden, May 30, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the Jefferies 2013 Global Healthcare Conference held
June 3-6, 2013 in New York, US. During the presentation, an update regarding
Active Biotech's development programs will be provided.

The presentation will include the laquinimod project, a novel oral
immunomodulatory drug primarily for the treatment of multiple sclerosis,
licensed to Teva Pharmaceutical, the Phase III prostate cancer project
tasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech's
novel concept for tumor therapy of primarily renal cell cancer. Also, the
project 57-57 (paquinimod) and the pre-clinical ISI project will be
presented.

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com.

The presentation will take place on June 4, at 4:00 pm EDT (Eastern Daylight
Time) / 22.00 Central European Summer Time.

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In addition, laquinimod is in Phase II development for Crohn's and Lupus. The
company also has one additional project in clinical development, the orally
administered compound paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.

Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 10:00 a.m. CEST on May 30, 2013.

Contacts:
Active Biotech AB
Hans Kolam, CFO
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00


[HUG#1705531]